At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Tamoxifen Citrate +4 moredrug
Likely dose
Tamoxifen Citrate 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Tamoxifen Citrate, Letrozole, and 3 other interventions for Breast Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsAgendia
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedOct 2019
Primary CompletionNov 2022
TodayJul 2026
First PostedOct 16, 2019
Enrollment StartFeb 20, 2019
Primary CompletionNov 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.7 years ago
Interventions
Tamoxifen Citratedrug
10mg administered daily. Patients take this drug for 2-6 weeks
Letrozoledrug
2.5mg is administered daily. Patients take this drug for 2-6 weeks
Exemestanedrug
25mg is administered daily. Patients take this drug for 2-6 weeks.
Blueprintother
studies the genomics of the tumor and tumor behavior
Mammaprintother
studies the genomics of the tumor